Hereditary Angioedema Therapeutic Market

Report Highlights

The scope of this report is broad and covers different drug class of hereditary angioedema therapeutic, along with the treatment types for hereditary angioedema therapeutic and hereditary angioedema therapeutic. The market is broken down by drug class of hereditary angioedema therapeutic, treatment types and regional markets. Revenue forecasts from 2019 to 2025 are given for each major drug class of hereditary angioedema therapeutic, treatment type and regional market, and the estimated values are derived from the manufacturers’ total revenues.

The report also includes a discussion of the major players across each of the regional hereditary angioedema therapeutic markets; it explains the major market drivers of the global hereditary angioedema therapeutic industry, current trends within the industry, major Treatment Types and the regional dynamics of the global hereditary angioedema therapeutic market.

The report concludes with a special focus on the vendor landscape, which includes detailed profiles of the major vendors in the global hereditary angioedema therapeutic industry.

Report Includes

• 62 tables
• An up-to-date analysis of the global hereditary angioedema therapeutic market.
• Analyses of the global market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026.
• Estimation of market size and revenue forecast for global Hereditary Angioedema Therapeutic market, and corresponding market share analysis by drug class, treatment Drug Class, route of administration and region for each market segment.
• Highlights of emerging technology trends, gaps and opportunities in the market estimating current and future demand for hereditary angioedema therapeutic, identification of the companies that are best positioned to meet this demand.
• In-depth information (facts and figures) concerning market drivers, restraints and other forces affecting the progress of this market.
• Identification of new products and products still in the development and their probability of successful commercial launch within the next five years
• Impact of COVID-19 on the hereditary angioedema therapeutic market as compared to overall global economy.
• Insight into the growth development strategies of major hereditary angioedema Therapeutic manufacturers and their key competitive landscape
• Descriptive company profiles of the leading market participants, including CSL Limited, Attune, Ionis Pharmaceuticals, Inc., Shire Plc (Takeda), BioCryst Pharmaceuticals, Inc., Pharming Group N.V., Pharmaceuticals, Inc. and Adverum Biotechnologies, Inc.

Summary

Hereditary angioedema is an autosomal disorder, where the functional C1 esterase inhibitor protein level is less. This results in an increased concentration of bradykinin, which leads to fluid leakage from the blood vessels, along with swelling. Filtered concentrate of C1 esterase inhibitor is infused to HAE - affected patients for the prophylactic and acute attack treatment of HAE. Various drugs have been approved for the prophylactic and acute attack treatment of hereditary angioedema.

As per the drug class, the different drug classes include C1-esterase inhibitor, Kallikrein inhibitor, B2 bradykinin receptor antagonist, and other drugs. Among which the C1-esterase inhibitor registered the major share in the market.